Merck KGaA (OTCMKTS:MKGAF) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Merck KGaA (OTCMKTS:MKGAF) from a sell rating to a hold rating in a research note published on Tuesday, ValuEngine reports.

Merck KGaA stock opened at $115.45 on Tuesday. The firm has a fifty day moving average of $117.86 and a 200-day moving average of $108.80. Merck KGaA has a 52-week low of $96.00 and a 52-week high of $121.40. The company has a quick ratio of 0.68, a current ratio of 0.94 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $14.92 billion, a P/E ratio of 20.44 and a beta of 0.69.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

See Also: Key terms to understand channel trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.